Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome

Basit Öğe Kaydı
dc.authoridEngin-Ustun, Yaprak/0000-0002-1011-3848
dc.authorwosidÜstün, Yusuf/AAC-2674-2020
dc.authorwosidUstun, Yaprak/KFQ-9767-2024
dc.contributor.authorOzkaya, Mesut
dc.contributor.authorCakal, Erman
dc.contributor.authorUstun, Yusuf
dc.contributor.authorEngin-Ustun, Yaprak
dc.date.accessioned2024-08-04T20:32:16Z
dc.date.available2024-08-04T20:32:16Z
dc.date.issued2010
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: To evaluate serum visfatin levels and to determine the effects of metformin treatment on visfatin levels in patients with polycystic ovary syndrome (PCOS). Design: Cross-sectional study. Setting: University hospital. Patient(s): Nineteen patients with PCOS and 21 controls. Intervention(s): Metformin was given to patients with PCOS, and serum visfatin levels were measured before and after treatment. Main Outcome Measure(S): Glucose, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, DHEAS, total T, insulin, homeostatic model assessment for insulin resistance (HOMA-IR), and visfatin levels were measured. Result(s): Serum visfatin levels were significantly higher in women with PCOS than in controls. Visfatin could differentiate between women with and without increased diabetogenic risk at a cut-off value of 19.24 ng/mL, with a sensitivity of 93.3% and a specificity of 84%. In bivariate analysis of subjects, T, insulin, and waist circumference were significantly and positively correlated with visfatin. Treatment resulted in a significant decrease in body mass index and a decrease in visfatin concentration. After therapy, statistically significant decreases in HOMA-IR, fasting insulin, free T, and DHEAS concentrations were observed for the PCOS group. Conclusion(s): Circulating visfatin levels were higher in patients with PCOS than healthy controls, and metformin treatment significantly reduced circulating visfatin concentrations after 3 months of therapy. (Fertil Steril (R) 2010:93:880-4. (C)2010 by American Society for Reproductive Medicine.)en_US
dc.identifier.doi10.1016/j.fertnstert.2008.10.058
dc.identifier.endpage884en_US
dc.identifier.issn0015-0282
dc.identifier.issn1556-5653
dc.identifier.issue3en_US
dc.identifier.pmid19111298en_US
dc.identifier.scopus2-s2.0-75749115194en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage880en_US
dc.identifier.urihttps://doi.org/10.1016/j.fertnstert.2008.10.058
dc.identifier.urihttps://hdl.handle.net/11616/94966
dc.identifier.volume93en_US
dc.identifier.wosWOS:000274957300029en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofFertility and Sterilityen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectType-2 Diabetes-Mellitusen_US
dc.subjectInsulin-Resistanceen_US
dc.subjectPlasma Visfatinen_US
dc.subjectWomenen_US
dc.subjectHyperandrogenismen_US
dc.subjectGlucoseen_US
dc.subjectReleaseen_US
dc.subjectFaten_US
dc.titleEffect of metformin on serum visfatin levels in patients with polycystic ovary syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu